Early Detection of Prostate Cancer by FACS
FACS
1 other identifier
observational
40
1 country
1
Brief Summary
Early detection of prostrate cancer and development of metastases. The research will attempt to match the SCM test (structuredness of the cytoplasmic matrix) in lymphocytes as an early cancer detection test using Florescent Activated Cell Sorting (FACS) as a replacement for the CellScan instrument. The test is based on measurement of cellular changes in response to the specific prostate antigen, PSA.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2007
CompletedFirst Submitted
Initial submission to the registry
September 3, 2007
CompletedFirst Posted
Study publicly available on registry
September 5, 2007
CompletedSeptember 5, 2007
August 1, 2007
September 3, 2007
September 4, 2007
Conditions
Keywords
Study Arms (4)
1
10 diagnosed men in age 60 - 90 with Prostate Cancer
2
10 patients with benign growth
3
10 health volunteers
4
10 patients diagnosed with other cancer
Eligibility Criteria
You may qualify if:
- Experimental group : Males between the ages of 60-90 years, with medical diagnosis of prostate cancer according to both clinical and hematological examinations, before receiving any medical treatment.
- Control Group 1: Males between the ages of 60-90 years, with diagnosed benign prostate hyperplasia -BPH.
- Control Group 2: Males between the ages of 60-90 years, medically diagnosed as healthy.
- Control Group 3: Males between the ages of 60-90 years, medically diagnosed with another form of cancer, not prostate.
You may not qualify if:
- Experimental group: Other known cancer or systemic infection. Control Group 1: Other known cancer or systemic infection. Control Group 2:Past hematological disorders nor cancer growth history. other known systemic infection, nor urinary tract infection. Patients hospitalized for orthopedic injuries of any type who are otherwise free of urinary tract infections.
- Control Group 3:Other known systemic infection, nor urinary tract infection.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ziv Hospitallead
Study Sites (1)
Urology Department, Ziv Medical Center
Safed, 20100, Israel
Related Publications (4)
Klein O, Lin S, Embon O, Sazbon A, Zidan J, Kook AI. An approach for high sensitivity detection of prostate cancer by analysis of changes in structuredness of the cytoplasmic matrix of lymphocytes specifically induced by PSA-ACT. J Urol. 1999 Jun;161(6):1994-6.
PMID: 10332488BACKGROUNDAltman, Roberta. The prostate Answer Book. Warner Books, lnc., 1993.
BACKGROUNDAmerican Cancer Society. National Cnference on Prostate Cancer. Philadelphia, Pennsylvania: September/October 1994.
BACKGROUNDRous, Stephen N., M.D.; The prostate Book. W.W. Norton & Co., 1992.
BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nina Kucherski, MD
Ziv Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- DEFINED POPULATION
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
September 3, 2007
First Posted
September 5, 2007
Study Start
August 1, 2007
Last Updated
September 5, 2007
Record last verified: 2007-08